Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alumis Inc. - Common Stock (NQ:ALMS)

9.470 -12.340 (-56.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alumis Inc. - Common Stock

News headline image
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
Via AB Newswire
News headline image
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
From Alumis Inc.
Via GlobeNewswire
News headline image
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today 
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Alumis and ACELYRIN Announce Amended Merger Agreement
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Alumis to Participate in Upcoming September Investor Conferences
From Alumis Inc.
Via GlobeNewswire
News headline image
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
From Alumis Inc.
Via GlobeNewswire
News headline image
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
From Alumis Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.